Verification of the effects of calcium channel blockers on the immune microenvironment of breast cancer

BMC Cancer

Table 3 Univariate and multivariate analysis with respect to DFS in TNBC

Parameters	Univarite analysis			Multivariate analysis
Parameters	Hazard ratio	95% CI	p value	Hazard ratio	95% CI	p value
Age at opetation (yr)
≤ 55 vs > 55	0.758	0.320–1.682	0.501
Tumor size (mm)
≤ 50 vs > 50	2.718	1.056–6.245	0.039	1.264	0.464–3.165	0.630
Skin infiltration
Negative vs Positive	2.349	0.781–5.806	0.118
Lymph node status
Negative vs Positive	2.664	0.922–11.261	0.073	1.954	0.634–8.522	0.263
Ki67
≤ 15% vs > 15%	1.700	0.587–7.197	0.359
Objective response rate
Non-Responders vs Responders	0.146	0.065–0.342	< 0.001	0.258	0.106–0.638	0.004
Pathological response
Non-pCR vs pCR	0.207	0.060–0.545	0.001	0.395	0.108–1.166	0.095
TILs
Low vs High	0.306	0.125–0.689	0.004	0.464	0.180–1.120	0.088
Hypertension
No vs Yes	2.212	0.735–5.476	0.145
Multiple types of AHT
No vs Yes	1.309	0.210–4.431	0.725
Calcium channel blockers
No vs Yes	1.601	0.379–4.627	0.472
ACEi or ARBs
No vs Yes	1.554	0.249–5.265	0.574
Beta-blockers
No vs Yes	0.894	0.050–4.229	0.911
Diuretics
No vs Yes	2.850	0.159–13.551	0.378

DFS Disease-free survival, TNBC triple-negative breast cancer, CI confidence intervals, pCR pathological complete response, TILs tumor- infiltrating lymphocytes, AHT antihypertensive drug, ACEi angiotensin-converting-enzyme inhibitors, ARBs angiotensin II receptor blockers

ISSN: 1471-2407